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Abstract
In 2011, an interlaboratory quality control (QC) program for emm typing group A streptococci 
(GAS) was incorporated into existing international circumpolar surveillance QC programs. From 
2011 – 2015, 35 GAS isolates were distributed to three laboratories; emm type-level concordance 
was 100%, while the overall sub-type level concordance was 83%.
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The International Circumpolar Surveillance (ICS) program was established to enhance the 
surveillance of infectious diseases of special interest to the circumpolar regions (Parkinson 
et al., 1999; Zulz et al., 2009). This program was initiated in 1999 and initially focused on 
the surveillance of invasive pneumococcal disease (IPD) in the U.S. Arctic (Alaska) and 
northern Canada. Soon thereafter, other northern countries joined (Greenland, Iceland, 
Norway, Finland, and Sweden) and the program has expanded to cover surveillance of other 
invasive bacterial diseases including Neisseria meningitidis, Haemophilus influenzae, 
Streptococcus pyogenes (Group A Streptococcus, GAS) and S. agalactiae (Group B 
Streptococcus, GBS) (Parkinson et al., 2008).
Essential to the success of any international surveillance program is the need to be able to 
compare results between testing laboratories, which are often generated by using different 
methodologies. In 1999, with the formation of the ICS program for the surveillance of IPD, 
an interlaboratory quality control (QC) program was introduced serving as an external 
proficiency testing mechanism for the serotyping and antibiotic susceptibility testing of 
Streptococcus pneumoniae (Reasonover et al., 2011). A similar program that monitors 
laboratory proficiencies in the serogrouping of N. meningitidis and serotyping of H. 
influenzae was introduced into the ICS program in 2005 (Tsang et al., 2012). In 2011, a 
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program that monitors laboratory proficiency in the emm typing of GAS was co-developed 
by the Centers for Disease Control and Prevention’s Arctic Investigation Program located in 
Anchorage, Alaska and the Public Hsealth Agency of Canada’s National Microbiology 
Laboratory located in Winnipeg, Ontario. In addition to the Anchorage and Winnipeg 
laboratories, the Provincial Laboratory for Public Health, located in Edmonton, Alberta also 
participates in this program. Here we describe the interlaboratory quality control program 
for emm typing of GAS isolates and present data collected from the first 5 years of this 
program (2011–2015).
From 2011 through 2015, five panels consisting of seven isolates of S. pyogenes were 
distributed annually among the three participating laboratories. Each participating laboratory 
was responsible for the selection and distribution according to a pre-defined distribution 
schedule. GAS isolates were selected to represent a variety of emm sequence types 
excluding isolates known to be non-typeable. The selected isolates were labeled according to 
the year and distribution event, e.g. 15GAS01, 15GAS02, etc. and testing personnel were not 
involved in isolate selection. All isolates were placed in charcoal transport media or on 
chocolate agar slants and shipped according to International Air Transportation Association 
regulations.
DNA lysates for emm typing were prepared as follows: Anchorage and Edmonton prepared 
DNA lysates according to the lysate preparation protocol described on the Centers for 
Disease Control and Prevention (CDC) website (http://www.cdc.gov/streplab/protocol-emm-
type.html); Winnipeg prepared DNA lysates using the Epicentre Bacterial Quick Extract kit 
(Mandel Scientific, Guelph, Ontario, Canada). The emm gene was amplified using the 
primer sequences listed on the CDC website. PCR master mix and cycling conditions varied 
between labs (Table 1). Purification of PCR products to serve as the sequencing templates 
were prepared as follows: ExoSAP-IT® (Affymetrix, Santa Clara, CA; Anchorage), 
PCRClean DX™ (Aline Biosciences, Woburn MA; Winnipeg) and QIAquick PCR 
purification kit for gel blocks (Qiagen, Germantown, MD; Edmonton). All three laboratories 
used the CDC protocol for sequencing the emm gene. Sequence analysis was performed by a 
BLAST search on the CDC streptococcal emm sequence database (http://www2a.cdc.gov/
ncidod/biotech/strepblast.asp) to designate emm sequence type.
A standardized report form to ensure consistent data collection was sent by the distributing 
laboratory with each QC panel. The information collected on the report form included 
isolate identifiers and emm results to the type level, (e.g. emm 4.4was reported as emm 4). 
The rationale for reporting results to the type-level only were two-fold: 1) historically, 
reference laboratories routinely reported emm results only to the type level, therefore this 
EAQ program was similarly structured; and 2) emm type-level data correlates more closely 
to the traditional M serotypes so type level results were readily recognizable to what clients 
were used to receiving. The distributing laboratory is responsible for compiling a summary 
report of the results, and if discrepant results are noted, the distributing lab may initiate a 
discussion to assist with troubleshooting.
During the first five years (2011–2015) of this quality control program, a total of 35GAS 
isolates were distributed among the three participating laboratories. The emm types of the 
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QC organisms are described in Table 2. The distributed isolates represented 24 emm types of 
which emm types 2, 3, 4, 6, 8, 34, 41, 75, 76, 77, 78, 82, 87, 94, 95, 108, and 118 were 
represented once while emm types 1, 12, 11, 28, 53, 89 and 91 were each represented two or 
more times. Over the five year period of this QC program our results showed 100% 
concordance in GAS emm typing at the type-level among the participating laboratories. 
However, one laboratory had differences at the subtype level, e.g. 1.38 instead of 1.0, 94.2 
instead of 94.0 (Table 2) leading to an overall subtype-level concordance of 83%. These 
differences could be due to sequencing errors or the quality of the sequences obtained.
Strain characterization of GAS was traditionally based on serological identification of the M 
protein which is a major surface protein and an important GAS virulence factor. Classical 
serologic M typing inmost laboratories has been replaced by emm typing, which in almost 
all cases, predicts the classical M serotype (Athey et al., 2014; Beall et al., 1991) and to date 
over 200 emm-types have been recognized. Although greater than 200 emm types have been 
described, only a limited number of types have been associated with invasive GAS disease. 
For example, in Alaska between 2001 and 2013, 516 cases of invasive GAS disease were 
reported of which 422 had isolates available for laboratory analysis. Among these 422 
isolates, 51 emm types were identified (Rudolph et al., 2016).
Other phenotypic techniques used to characterize GAS isolates include the characterization 
of cell surface T protein antigens and serum opacity factor production (Johnson et al., 2006). 
While both of these methods can add an additional level of resolution when combined with 
emm typing, the availability of antisera is limited. Many laboratories have therefore moved 
away from using phenotypic techniques and rely strictly on molecular methods for GAS 
typing.
Because infectious diseases are a global threat, their prevention and control is aided by 
international collaboration of which surveillance is a key component. The International 
Circumpolar Surveillance program creates an infectious disease surveillance network of 
hospital and public health laboratories and authorities throughout Arctic regions. This 
surveillance program allows for the standardized collection, comparison and sharing of 
laboratory and epidemiologic data on invasive GAS disease and assists in the formulation of 
prevention and control strategies. Another international surveillance collaboration includes 
the strep-EURO project launched in 2002 to enhance understanding of the epidemiology of 
invasive GAS disease in Europe (Neal et al., 2007). One of the objectives of this project was 
to improve GAS strain characterization by harmonizing methods and establishing an 
external quality assurance program (EQA). The EQA study included both phenotypic and 
molecular typing methods. Among 15 participating centers that performed emm typing, an 
overall concordance of 98% for emm type-level data was achieved, similar to what is 
reported in this study. Also, there was variation in the interpretation of emm subtypes, which 
was also reported here and highlights difficulties when assigning subtypes. High 
concordance (90%) for emm typing was also reported in a previous EQA exercise conducted 
from 1997–1999 by this same group (Efstratiou et al., 2000). The few incorrect results 
reported in this exercise were mainly due to mismatches and variability in the interpretation 
of sequence data due to the lack of an officially recognized and designated database which 
has since been established. It should be noted that the aforementioned EQA exercises were 
Rudolph et al. Page 3
Diagn Microbiol Infect Dis. Author manuscript; available in PMC 2017 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
conducted prior to the release of new parameters for assigning types to emm sequence data. 
New types are now identified on the basis of sharing less than 92% sequence identity over 
the first 90 bases encoding the deduced processed M protein of the emm type reference 
strain. This report represents the first EQA study performed since the changes took effect 
and highlights the accurate and reliable nature of this GAS typing method.
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Table 2
Emm type results for the quality control isolates of the International Circumpolar Surveillance program, 2011–
2015.
Year No. of isolates emm types % Concordance to type level (no. of concordant results/total no. of 
tests)
2011 7 1.0*, 4.0, 12.8, 28.0, 75.0, 87.0, 89.0 100 (7/7)
2012 7 3.1, 76.1, 78.3, 82.0*, 89.0(2), 94.0* 100 (7/7)
2013 7 2.0, 6.0, 11.0, 41.2, 53.0*, 77.0, 91.0 100 (7/7)
2014 7 1.0, 8.0, 12.0*, 28.0*, 89.0, 91.0, 118.0 100 (7/7)
2015 7 1.0, 11.0, 34.0, 53.1, 91.0, 95.0, 108.1 100 (7/7)
*
Denotes differences at the subtype level for these emm types (1.38, 94.2, 82.3, 53.1, 12.76, 28.4).
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